Eukaryotic translation initiation factor 3H suppression inhibits osteocarcinoma cell growth and tumorigenesis

Hong,Song; Liu,Yi; Xiong,Huazhang; Cai,Dongfeng; Fan,Qinghong

doi:10.3892/etm.2018.6031

Eukaryotic translation initiation factor 3H suppression inhibits osteocarcinoma cell growth and tumorigenesis

Authors:
- Song Hong
- Yi Liu
- Huazhang Xiong
- Dongfeng Cai
- Qinghong Fan
View Affiliations

Affiliations: Department of Orthopedics, Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou 563003, P.R. China
Published online on: April 3, 2018 https://doi.org/10.3892/etm.2018.6031
Pages: 4925-4931
Copyright: © Hong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Eukaryotic translation initiation factor 3H subunit (EIF3H) is a member of the EIF3 family and exhibits a central role in translation initiation in higher eukaryotes. Although EIF3H expression is upregulated in numerous tumour types, its potential role in human osteosarcoma (OS) has not yet been investigated. In the present study, it was demonstrated that EIF3H mRNA expression was upregulated in the human OS cell lines Saos‑2 and U2OS. A recombinant lentivirus harbouring short hairpin RNA targeting EIF3H was constructed and successfully infected human OS Saos‑2 and U2OS cells, resulting in 95% downregulated EIF3H expression compared with the respective control groups. Knockdown of EIF3H significantly inhibited the proliferation and colony formation of OS cells in vitro, and tumour growth in nude mice in vivo. Flow cytometry analysis revealed cell cycle arrest and promotion of apoptosis in OS cells with EIF3H knocked down. In conclusion, the results strongly suggested that EIF3H is a critical factor mediating the growth of OS cells and may represent a novel therapeutic target.

View Figures

View References

1	Isakoff MS, Bielack SS, Meltzer P and Gorlick R: Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 33:3029–3127. 2015. View Article : Google Scholar : PubMed/NCBI
2	Gill J, Ahluwalia MK, Geller D and Gorlick R: New targets and approaches in osteosarcoma. Pharmacol Ther. 137:89–99. 2013. View Article : Google Scholar : PubMed/NCBI
3	Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
4	Masutani M, Sonenberg N, Yokoyama S and Imataka H: Reconstitution reveals the functional core of mammalian eIF3. EMBO J. 26:3373–3383. 2007. View Article : Google Scholar : PubMed/NCBI
5	Rooney PH, Murray GI, Stevenson DA, Haites NE, Cassidy J and McLeod HL: Comparative genomic hybridization and chromosomal instability in solid tumours. Br J Cancer. 80:862–873. 1999. View Article : Google Scholar : PubMed/NCBI
6	Nupponen NN, Kakkola L, Koivisto P and Visakorpi T: Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol. 153:141–148. 1998. View Article : Google Scholar : PubMed/NCBI
7	Mahmood SF, Gruel N, Chapeaublanc E, Lescure A, Jones T, Reyal F, Vincent-Salomon A, Raynal V, Pierron G, Perez F, et al: A siRNA screen identifies RAD21, EIF3H, CHRAC1 and TANC2 as driver genes within the 8q23, 8q24.3 and 17q23 amplicons in breast cancer with effects on cell growth, survival and transformation. Carcinogenesis. 35:670–682. 2014. View Article : Google Scholar : PubMed/NCBI
8	Cappuzzo F, Varella-Garcia M, Rossi E, Gajapathy S, Valente M, Drabkin H and Gemmill R: MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib. J Thorac Oncol. 4:472–478. 2009. View Article : Google Scholar : PubMed/NCBI
9	Schefe JH, Lehmann KE, Buschmann IR, Unger T and Funke-Kaiser H: Quantitative real-time RT-PCR data analysis: Current concepts and the novel ‘gene expression's CT difference‘ formula. J Mol Med (Berl). 84:901–910. 2006. View Article : Google Scholar : PubMed/NCBI
10	Nupponen NN, Porkka K, Kakkola L, Tanner M, Persson K, Borg A, Isola J and Visakorpi T: Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol. 154:1777–1783. 1999. View Article : Google Scholar : PubMed/NCBI
11	Daxinger L, Oey H, Apedaile A, Sutton J, Ashe A and Whitelaw E: A forward genetic screen identifies eukaryotic translation initiation factor 3, subunit H (eIF3h), as an enhancer of variegation in the mouse. G3 (Bethesda). 2:1393–1396. 2012. View Article : Google Scholar : PubMed/NCBI
12	Zhu Q, Qiao GL, Zeng XC, Li Y, Yan JJ, Duan R and Du ZY: Elevated expression of eukaryotic translation initiation factor 3H is associated with proliferation, invasion and tumorigenicity in human hepatocellular carcinoma. Oncotarget. 7:49888–49901. 2016.PubMed/NCBI
13	Savinainen KJ, Helenius MA, Lehtonen HJ and Visakorpi T: Overexpression of EIFS3 promotes cancer cell growth. Prostate. 66:1144–1150. 2006. View Article : Google Scholar : PubMed/NCBI
14	Zhang L, Smit-McBride Z, Pan X, Rheinhardt J and Hershey JW: An oncogenic role for the phosphorylated h-subunit of human translation initiation factor eIF3. J Biol Chem. 283:24047–24060. 2008. View Article : Google Scholar : PubMed/NCBI
15	Choudhuri A, Maitra U and Evans T: Translation initiation factor eIF3h targets specific transcripts to polysomes during embryogenesis. Proc Natl Acad Sci USA. 110:9818–9823. 2013. View Article : Google Scholar : PubMed/NCBI
16	Ingolia NT, Ghaemmaghami S, Newman JR and Weissman JS: Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. Science. 324:218–223. 2009. View Article : Google Scholar : PubMed/NCBI
17	Roy B, Vaughn JN, Kim BH, Zhou F, Gilchrist MA and Von Arnim AG: The h subunit of eIF3 promotes reinitiation competence during translation of mRNAs harboring upstream open reading frames. RNA. 16:748–761. 2010. View Article : Google Scholar : PubMed/NCBI
18	Spilka R, Ernst C, Mehta AK and Haybaeck J: Eukaryotic translation initiation factors in cancer development and progression. Cancer Lett. 340:9–21. 2013. View Article : Google Scholar : PubMed/NCBI
19	Graff JR and Zimmer SG: Translational control and metastatic progression: Enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis. 20:265–273. 2003. View Article : Google Scholar : PubMed/NCBI
20	Zimmer SG, DeBenedetti A and Graff JR: Translational control of malignancy: The mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res. 20:1343–1351. 2000.PubMed/NCBI
21	Kim BH, Cai X, Vaughn JN and von Arnim AG: On the functions of the h subunit of eukaryotic initiation factor 3 in late stages of translation initiation. Genome Biol. 8:R602007. View Article : Google Scholar : PubMed/NCBI